Excalibur Management Corp Holds Stake in Amgen Inc. (AMGN)
Excalibur Management Corp continued to hold its position in shares of Amgen Inc. (NASDAQ:AMGN) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,605 shares of the medical research company’s stock at the end of the second quarter. Amgen makes up 1.0% of Excalibur Management Corp’s investment portfolio, making the stock its 25th largest position. Excalibur Management Corp’s holdings in Amgen were worth $1,138,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also modified their holdings of the company. Osborne Partners Capital Management LLC raised its position in Amgen by 0.5% in the second quarter. Osborne Partners Capital Management LLC now owns 17,023 shares of the medical research company’s stock valued at $2,932,000 after buying an additional 91 shares during the last quarter. Gilbert & Cook Inc. purchased a new position in Amgen during the second quarter valued at about $230,000. Duncker Streett & Co. Inc. raised its position in Amgen by 8.3% in the second quarter. Duncker Streett & Co. Inc. now owns 5,580 shares of the medical research company’s stock valued at $961,000 after buying an additional 430 shares during the last quarter. Huntington National Bank raised its position in Amgen by 1.2% in the second quarter. Huntington National Bank now owns 251,054 shares of the medical research company’s stock valued at $43,239,000 after buying an additional 3,090 shares during the last quarter. Finally, Bridges Investment Counsel Inc. raised its position in Amgen by 82.4% in the second quarter. Bridges Investment Counsel Inc. now owns 25,869 shares of the medical research company’s stock valued at $4,455,000 after buying an additional 11,688 shares during the last quarter. Institutional investors and hedge funds own 78.12% of the company’s stock.
Amgen Inc. (NASDAQ:AMGN) traded up 0.06% during trading on Tuesday, reaching $171.88. 563,308 shares of the company’s stock were exchanged. Amgen Inc. has a 12 month low of $133.64 and a 12 month high of $184.21. The stock has a market cap of $125.42 billion, a PE ratio of 15.66 and a beta of 1.35. The firm has a 50 day moving average of $173.53 and a 200-day moving average of $168.31.
Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.11 by $0.16. The firm had revenue of $5.81 billion during the quarter, compared to analyst estimates of $5.67 billion. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The business’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same period in the previous year, the company posted $2.84 EPS. On average, equities research analysts anticipate that Amgen Inc. will post $12.57 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Thursday, August 17th will be given a dividend of $1.15 per share. This represents a $4.60 annualized dividend and a yield of 2.68%. The ex-dividend date of this dividend is Tuesday, August 15th. Amgen’s dividend payout ratio is currently 41.93%.
AMGN has been the subject of several analyst reports. ValuEngine lowered shares of Amgen from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Oppenheimer Holdings, Inc. restated an “outperform” rating and set a $203.00 price target (up previously from $189.00) on shares of Amgen in a report on Wednesday, July 26th. BidaskClub upgraded shares of Amgen from a “buy” rating to a “strong-buy” rating in a research note on Friday, June 23rd. BMO Capital Markets lowered shares of Amgen from an “outperform” rating to a “market perform” rating in a research note on Wednesday, July 26th. Finally, Argus lifted their price objective on shares of Amgen from $180.00 to $195.00 and gave the company a “buy” rating in a research note on Thursday, July 27th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $186.04.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.